CD19 CAR-T细胞治疗进展性系统性硬化症的临床与蛋白组学整合分析
该研究对进展性系统性硬化症(SSc)患者给予CD19 CAR-T细胞治疗并进行纵向观察,评估安全性、临床疗效、免疫重建及血浆蛋白组学变化。结果显示治疗安全性可控,皮肤受累及患者与医生评估的疾病活动度等多个领域持续改善,并伴随B细胞快速清除与免疫重建,蛋白组学提示炎症与纤维化通路广泛减弱、修复相关过程相对增强。
要点
- CD19 CAR-T治疗进展性SSc安全性可控,多疾病领域临床持续改善
- 治疗诱导B细胞快速清除并随后出现免疫重建
- 蛋白组学显示炎症与纤维化程序减弱、修复相关过程相对增强
核心结论
- Relma-cel治疗SSc患者带来早期临床改善,并有CAR-T细胞扩增、B细胞清除和良好安全性特征支持。
- 蛋白组学改变与观察到的临床改善相关,提示炎症和纤维化通路发生广泛重塑。
研究设计与样本
- 进展性SSc患者接受CD19 CAR-T细胞治疗并纵向观察安全性、临床疗效、免疫重建和血浆蛋白组学变化。
- 临床评估包括皮肤、肺、血管、患者报告和医生报告结局。
- 血浆蛋白在基线和治疗后多个时间点用SomaScan平台检测,分析差异蛋白丰度和通路水平变化。
主要发现
- 治疗安全性可控,皮肤受累及患者和医生评估的疾病活动度等多个SSc疾病领域持续改善。
- 治疗诱导B细胞快速清除,随后出现免疫重建。
- 纵向蛋白组学显示炎症、纤维化、血管重塑和免疫调节相关蛋白与通路出现协调性变化。
- 第180天差异蛋白分析显示多个SSc相关蛋白发生治疗相关变化,包括促纤维化或炎症活性相关蛋白下调、血管修复或免疫调节相关蛋白上调。
- 通路水平分析支持炎症和纤维化程序广泛减弱、修复相关生物学过程相对增强。
关键数值与推荐
- 第180天差异蛋白分析识别出多个SSc相关蛋白的治疗相关变化。
- 通路水平分析显示炎症与纤维化程序广泛减弱、修复相关过程相对增强。
临床怎么用
- 结果提示CD19 CAR-T细胞治疗在进展性SSc中具有可控安全性和多领域临床改善信号,值得进一步研究。
- 蛋白组学变化可作为探索治疗相关分子重塑的线索,但需更大样本研究验证。
局限性
- 结论指出需要更大样本量的进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). METHODS: Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)-T cell therapy and were observed longitudinally for safety, clinical efficacy, immune reconstitution, and plasma proteomic changes. Clinical assessments included skin, pulmonary, vascular, patient-reported, and physician-reported outcomes. Plasma proteins were profiled at baseline and serial post-treatment time points using the SomaScan platform. Differential protein abundance and pathway-level changes were analyzed to explore treatment-associated molecular remodeling. RESULTS: CD19 CAR-T cell therapy was associated with manageable safety profiles and sustained clinical improvement across multiple SSc disease domains, including skin involvement and patient- and physician-assessed disease activity. Treatment induced rapid B cell depletion followed by immune reconstitution. Longitudinal proteomic profiling revealed coordinated changes in proteins and pathways related to inflammation, fibrosis, vascular remodeling, and immune regulation. At day 180, differential protein analysis identified treatment-associated shifts in multiple systemic sclerosis-relevant proteins, including down-regulation of proteins linked to profibrotic or inflammatory activity and up-regulation of proteins potentially associated with vascular repair or immune regulation. Pathway-level analyses further supported broad attenuation of inflammatory and fibrotic programs with relative enhancement of repair-associated biologic processes. CONCLUSION: Relma-cel therapy in patients with SSc led to early clinical improvement, supported by CAR-T cell expansion, B cell depletion, and a favorable safety profile. Proteomic alterations were associated with the observed clinical improvements and suggested broad remodeling of inflammatory and fibrotic pathways. Further studies with larger sample sizes are warranted.
引用
- Jia C, Lin W, Zhao Z, et al. Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis. Arthritis Rheumatol. 2026. PMID: 42223209. doi:10.1002/art.70236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。